BETHESDA, Md., May 4, 2016 -- The Bladder Cancer Advocacy Network is pleased to announce the appointment of Andrea Maddox-Smith as Chief Executive Officer, effective May 2.
Maddox-Smith is an innovative and energetic leader with extensive experience in non-profit management, program development and fundraising. Prior to joining BCAN, Maddox-Smith served in a variety of leadership roles at the American Diabetes Association for 16 years, most recently as the senior vice president, Eastern division/nationwide mission delivery. In this role, she oversaw all aspects of operations management, new business development, staff management and volunteer recruitment.
"We are thrilled to have Andrea on board," said Diane Zipursky Quale, co-Founder of BCAN. "We know that she will inspire the bladder cancer community and marshal the people and resources necessary to collaboratively implement BCAN's mission and ensure the organization's continued growth and impact."
The new leadership comes at a critical time in the organization's history with the recent introduction of the Bladder Cancer Genomics Consortium. A collaboration with BCAN and major medical institutions, the consortium is designed to increase research to improve outcomes for bladder cancer patients.
"I strive to create a sense of urgency around this disease that would allow every newly diagnosed bladder cancer patient access to BCAN resources," said Maddox-Smith. "I am excited to bring a progressive and results oriented approach and vision to the organization by collaborating with the many volunteers, researchers, clinicians and members."
About the Bladder Cancer Advocacy Network
The Bladder Cancer Advocacy Network's mission is to increase public awareness about bladder cancer, advance bladder cancer research, and provide educational and support services for the bladder cancer community. BCAN serves as the leading voice for bladder cancer in the U.S., providing resources to not only those diagnosed with the disease but their families, caregivers and the medical community united in support of people impacted by the disease. The organization is setting the agenda for bladder cancer by promoting and funding collaborative and cutting-edge research programs and providing critical patient support and education services. BCAN works collaboratively with the medical and research professionals dedicated to the prevention, diagnosis, and treatment of bladder cancer, and empowers the patient community by allowing them to share experiences with others and to participate in building awareness of the need for a cure. For more information go to www.bcan.org or call 1-888-901-BCAN (2226).
CONTACT: Natalie Bennett
Email: [email protected]
Phone: 301.215.9099 ext 202


MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
OpenAI Addresses Security Vulnerability in macOS App Certification Process
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Bill Ackman Eyes New Fund to Bet Against Market Complacency
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 



